An oncologist from Atrium Health outlines how saving time administering immunotherapy could have far-reaching benefits.

Both Merck & Co. and Halozyme are holding their ground in a freshly unveiled patent dispute surrounding the New Jersey pharma ...

Opdivo Qvantig (nivolumab and hyaluronidase ... The switch from the original IV formulations improves the ease of administration for the drugs, reducing the time patients have to spend in clinics ...

which enrolled people with stage III-IV melanoma that had been completely surgically removed. Opdualag did not perform significantly better than Opdivo on the primary endpoint of recurrence-free ...

Advantage Solutions Inc. ("Advantage," "Advantage Solutions," the "Company," "we," or "our"), a leading business solutions provider to consumer goods manufacturers and retailers, ...

Opdivo plus Yervoy showed a median overall survival of 23.7 months vs. 20.6 months with lenvatinib or sorafenib in the CheckMate -9DW trial. The overall response rate for Opdivo plus Yervoy was 36 ...

Bristol Myers (BMY) Squibb announced that the European Commission has approved Opdivo plus Yervoy for the first-line treatment of adult patients with unresectable or advanced hepatocellular carcinoma.

This approval is grounded in the results from the Phase 3 CheckMate -9DW study, which indicated a notable improvement in overall survival for patients treated with the Opdivo plus Yervoy ...

Bristol Myers Squibb has won the European Commission's expanded approval of its Opdivo plus Yervoy cancer-drug combination for early use in certain patients with liver cancer. Bristol Myers on ...